Clinical Cardiology Alert – September 1, 2006
September 1, 2006
View Issues
-
The Bear is Out of the Lair: The Emerging Importance of Diastolic Heart Failure
Heart failure today is the focus of enormous growth of interest in research, clinical trials, and improved care. A number of factors are responsible for the increasing prominence of congestive heart failure (CHF). -
ACE Inhibitors and Renal Function
Reduced renal function may define a subset of patients most likely to benefit from ACE-inhibitor therapy for cardiovascular protection. -
Comparative Analysis of Biomarkers
Although levels of various inflammatory biomarkers are significantly related to future cardiovascular risk, their incremental predictive value is modest. -
Major Complications of Implantable Cardioverter-Defibrillators
In fiscal 2003, 10.8% of Medicare patients undergoing cardioverter-defibrillator implantation experienced one or more early complications, associated with significant increases in LOS and costs. -
Defibrillation Thresholds in ICDs
DFT reassessment after the institution of antiarrhythmic drug therapy with amiodarone or sotalol is not routinely required. -
Atrioventricular Nodal Reentrant Tachycardia in Patients with Atrial Fibrillation
Ablation of AVNRT in patients with AF was associated with improved outcomes compared with those with other triggers of AF. -
Pharmacology Watch
What is the role of raloxifene for the treatment of osteoporosis and breast cancer prevention? Raloxifene is a selective estrogen-receptor modulator similar to tamoxifen. -
Clinical Briefs in Primary Care Supplement